Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E-SEMPA: Early Combination Treatment in Short Duration Type 2 Diabetes
NCT06613854Phase 4Recruiting
- Sponsor
- University Medical Centre Ljubljana
- Start
- Oct 2024
- Primary completion
- Sep 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of semaglutide and empagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by University Medical Centre Ljubljana. Primary endpoint: Time in Range at 26 weeks. Started Oct 2024; status: recruiting.
02
Drugs
semaglutideempagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06613854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06613854.